A pharmaceutical composition is described. The composition comprises a formulation. The formulation comprises an NMDA antagonist and an alpha-2 adrenergic agonist. In a preferred aspect, there is provided an improved anaesthetic comprising an NMDA antagonist and an alpha-2 adrenergic agonist.

 
Web www.patentalert.com

< Toxicity of boron compounds to certain arthropods

< Method of treating gastric ulcer by administration of epidermal growth factor

> Treatment of liposarcomas using a combination of thiazolidinediones and retinoid X receptor selective agonists

> Oral dosage self-emulsifying formulations of pyranone protease inhibitors
~ 00071